Astrazeneca Plc ADR (AZN)
$76.80
0.00 (0.00%)
AZN Stock Quote Delayed 30 Minutes
Who Has the Best Pharma Pipeline?
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
202
Day's Range
-
52-Week Range
$60.47 - $80.86
Dividend & Yield
$0.93 (1.21%)
AZN Stock Predictions, Articles, and Astrazeneca Plc ADR News
Pfizer Tops Q2 Earnings Estimates
Pfizer posted second-quarter earnings that topped Wall Street estimates even as revenue declined compared to last year.
AstraZeneca Tops Earnings Forecasts as Sales Fall
British pharmaceutical giant AstraZeneca posted second-quarter earnings that topped Wall Street's forecast for earnings, but fell short of revenue projections.
Novartis Wins Approval for Breast Cancer Drug
The FDA has granted approval for Novartis' drug Afinitor to be used as a treatment for breast cancer after it showed promise in clinical trials.
What’s the Real Impact of Generic Drugs?
The danger of patent expirations for big pharma isn't new, but the amount of market share those brands are losing to generics as a result are not pretty.
6 Flatlining Healthcare Stocks to Sell
Healthcare stocks are under pressure as patents expire and margins are pressed. Consider selling these 6 laggards from the portfolio.
AstraZeneca CEO Resigns, Shares Drop
CEO David Brennan departs after the company reported lower earnings and sales for the last quarter and a diminished outlook for the year.
Cue the Biotech M&A Attack!
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.
Stock Pick of The Day: Dyax
Dyax is a maker of anti-inflammation drugs, an area with a growing base of patients. While in the early stages of growth, the company shows great promise.
Here Comes a Bidding War for Amylin
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.
Amylin Perks Up on Rejection — Wednesday’s IP Market Recap
A spurned bid from Bristol-Myers Squibb sends AMLN up 54% on speculation that other offers will roll in.
Why Investors Needn’t Fear the ‘Patent Cliff’
Expiring drug patents can cost pharma stocks billions of dollars, but companies and investors alike can prepare themselves well in advance.
FDA Considers Waiving Prescription Requirement for Key Drugs
The FDA is considering a proposal to waive the prescription requirement for key drugs and encourage easy access to computer-supported self-diagnostic tools.
3 High-Yield Dividend Stocks to Avoid
Don't be tempted by the juicy payouts offered by these three well-known names. Those big dividends mask a lot of bigger problems.
5 Signs Unemployment Will Rise Again Soon
A steady drumbeat of large-scale layoffs and cutbacks could eventually cast a shadow over the recent 8.3% headline jobless rate.
Ranbaxy Closes In on FDA Approval for Generic Lipitor
Ranbaxy could sell $650 million worth of the drug in its first 180 days. But Pfizer is battling hard to keep branded Lipitor alive.
Forget Amgen — Buy This Pharmaceutical Stock Instead
Amgen is a world-class biotech company, but its big growth is a thing of the past. Another pharma stock is positioning itself for a place in your portfolio.
Big Pharma’s Emerging Markets Foray Hits Roadblocks
Companies are finding plans for global expansion aren't without hiccups.
Why Dentsply Is a Stock to Buy
The global dental products powerhouse Dentsply (XRAY) looks set to break higher.
Bristol-Myers, AstraZeneca Diabetes Drug Gets New Hope
Cleveland Clinic's positive review revitalizes Bristol-Myers, AstraZeneca's dapagliflozin, an experimental drug taking on a growing diabetes management market.
Should You Buy the Dow — Pfizer
Pfizer's financials are decent, as is its lineup of drugs and personal care products, but the stock is fully valued.
